FLT3 and acute myeloid leukemia: It achieved a higher CR/CRi of 66.7% in R/R AML patients carrying FLT3-ITD or FLT3-TKD mutations, suggesting BHA may be an option for R/R AML, particularly for FLT3-mutated those.